These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 15292283)

  • 21. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer.
    Fish SA; Basu S; Alavi A; Mandel SJ
    Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):560-3. PubMed ID: 20927023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
    Lassmann M; Luster M; Hänscheid H; Reiners C
    J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
    [No Abstract]   [Full Text] [Related]  

  • 23. Radiation exposure to the family of radioactive patients.
    Harbert JC; Wells N
    J Nucl Med; 1974 Oct; 15(10):887-8. PubMed ID: 4418007
    [No Abstract]   [Full Text] [Related]  

  • 24. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.
    Mallick U; Harmer C; Hackshaw A; Moss L;
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):159-61. PubMed ID: 22316618
    [No Abstract]   [Full Text] [Related]  

  • 26. Thyroid remnant ablation: questionable pursuit of an ill-defined goal.
    Riccabona G
    J Nucl Med; 1984 Jun; 25(6):727-8. PubMed ID: 6726447
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine.
    Rosário PW; Purisch S; Vasconcelos FP; Padrão EL; Rezende LL; Barroso AL
    Nucl Med Commun; 2007 Jun; 28(6):507-8. PubMed ID: 17460543
    [No Abstract]   [Full Text] [Related]  

  • 28. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected.
    Sisson JC
    J Nucl Med; 1983 Aug; 24(8):743-5. PubMed ID: 6875686
    [No Abstract]   [Full Text] [Related]  

  • 31. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
    Barbaro D; Boni G
    Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Struma ovarii in a patient with a history of papillary thyroid carcinoma.
    Ng L; Brennan B
    Pathology; 2006 Oct; 38(5):461-4. PubMed ID: 17008292
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
    Eustatia-Rutten CF; Smit JW; Romijn JA; van der Kleij-Corssmit EP; Pereira AM; Stokkel MP; Kievit J
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):61-74. PubMed ID: 15212646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it time to ditch 131I ablation?
    Buscombe JR; Taher MA
    Nucl Med Commun; 2007 Mar; 28(3):231; author reply 231-2. PubMed ID: 17264784
    [No Abstract]   [Full Text] [Related]  

  • 35. Radioactive iodine in thyroid medicine--how it started in Sweden and some of today's challenges.
    Mattsson S; Johansson L; Jönsson H; Nosslin B
    Acta Oncol; 2006; 45(8):1031-6. PubMed ID: 17118834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
    Reiners C; Biko J; Haenscheid H; Hebestreit H; Kirinjuk S; Baranowski O; Marlowe RJ; Demidchik E; Drozd V; Demidchik Y
    J Clin Endocrinol Metab; 2013 Jul; 98(7):3039-48. PubMed ID: 23616148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial radioiodine administration: when to use it and how to select the dose.
    Esposito G
    Endocrinol Metab Clin North Am; 2014 Jun; 43(2):385-400. PubMed ID: 24891168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials.
    Cohen AB; Brose MS
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1995-7. PubMed ID: 24893137
    [No Abstract]   [Full Text] [Related]  

  • 40. [Autonomous adenoma of the thyroid gland and radioiodine therapy].
    Kuchar O; Kraft O
    Vnitr Lek; 1987 Sep; 33(9):739-47. PubMed ID: 3672952
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.